Tevogen Bio Holdings (TVGN) rose 15.56% in premarket trading following D. Boral Capital’s decision to maintain a Buy recommendation on the stock as of November 20, 2025. The firm’s continued endorsement, signaling confidence in the biotechnology company’s prospects, likely spurred investor optimism ahead of the market open. The recommendation aligns with the stock’s upward trajectory, reflecting positive sentiment toward Tevogen’s strategic positioning or recent operational developments.
Comments
No comments yet